This segment introduces the program by emphasizing the critical role of comprehensive biomarker testing, including tissue-based next-generation sequencing, liquid biopsy, and immunohistochemistry, in guiding personalized treatment decisions for patients with non-small cell lung cancer.
This segment examines the operational aspects of biomarker testing in non-small cell lung cancer, emphasizing the importance of multidisciplinary collaboration and efficient institutional workflows to ensure timely molecular testing, while highlighting the limitations of conventional TROP2 immunohistochemistry in predicting response to antibody-drug conjugate therapies and the need for more precise approaches such as computational pathology.
Trop-2 ADC trials in lung cancer show H-score fails to predict benefit, spotlighting drug internalization and target engagement as key efficacy drivers.
Trop-2 levels alone fail to predict ADC response in lung cancer; an AI pathology biomarker (Trop-2 NMR) links cytoplasmic ratio to outcomes.
Real-world studies show high concordance for AI TRK2‑NMR scoring in lung cancer; next, phase III trials test clinical validation.
How Trop-2 NMR scoring may predict response to Trop-2 ADCs in NSCLC, why lower ratios matter, and what validation comes next.
Phase 3 trials test AI-scored Trop-2 NMR to guide first-line NSCLC ADC therapy, reshaping biomarker-driven treatment and lab adoption.
This final segment broadens the discussion beyond TROP2 to explore the broader implications of QCS and computational pathology for biomarker development and clinical practice. Dr. Wistuba explains that QCS represents a platform capable of objectively quantifying protein expression across multiple cellular compartments, including membrane, cytoplasmic, nuclear, and immune cell populations, using digital image analysis. This flexibility creates opportunities to apply the approach to a wide range of biomarkers, including additional ADC targets, immune markers, and even routine diagnostic proteins.
